Among the many promising factors from several key signaling pathways, we identified a novel mechanistic involvement of EGFR and NF-κB in the MYB signaling which needs to be further explored, particularly in the context of therapeutic targeting of MYB signaling in PC patients. This evidence concerns the gene NFKB1 and pachyonychia congenita.